Acadia Pharmaceuticals Inc
ACAD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001070494
In the last 90 days, Acadia Pharmaceuticals Inc insiders filed 0 open-market purchases and 1 sale; 354 institutions reported holding it in 13F filings for Q2 2026, worth $4.27B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $3.24B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $69.3K in total
- 1
- 13F holdersQ2 2026, +13 vs. previous quarter
- 354
- 13F valueReported value at the end of Q2 2026
- $4.27B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $1.07B
- +11.9% year over year
- Net income, FY2025
- $391.0M
- +72.7% year over year
- Free cash flow, FY2025
- $105.1M
- −33.1% year over year
- Revenue, Q3 FY2026
- $342.3M
- +22.8% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 8.32M
- Shares sold short
- Change
- −776.8K
- −8.5% vs. previous
- Days to cover
- 5.94
- At average daily volume
Superinvestors holding ACAD, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ACAD at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Acadia Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 30, 2026 (view filing)8:20 PM ET | Oct 30 | Same day | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | SSale | −3.32K | $20.88 | −$69.3K | −4.4%71.3K after | |
| Aug 7, 2026 (view filing)6:00 PM ET | Aug 5-6 | 2 days | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | SSale | −20.1K | $29.16 | −$587.2K | −22.9%67.8K after | 3 lots10b5-1 |
| Jul 31, 2026 (view filing)6:00 PM ET | Jul 30 | 1 day | Thompson Elizabeth H.Z.EVP, Head of Research & Dev | SSale | −16.6K | $26.13 | −$432.7K | −46.6%19.0K after | 2 lots |
| Jun 29, 2026 (view filing) | Jun 26 | 3 days | Kihara JamesPRINCIPAL ACCOUNTING OFFICER | SSale | −11.4K | $26.08 | −$297.9K | −46.6%13.1K after | 10b5-1 |
| May 27, 2026 (view filing) | May 26 | 1 day | Kihara JamesPRINCIPAL ACCOUNTING OFFICER | SSale | −5.40K | $21.18 | −$114.4K | −18.1%24.5K after | |
| May 5, 2026 (view filing) | May 4 | 1 day | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | SSale | −3.51K | $21.79 | −$76.4K | −5.0%66.1K after | |
| May 5, 2026 (view filing) | May 4 | 1 day | Kihara JamesPRINCIPAL ACCOUNTING OFFICER | SSale | −1.33K | $21.79 | −$29.0K | −4.4%29.1K after | |
| Apr 7, 2026 (view filing) | Apr 7 | Same day | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | SSale | −2.71K | $22.20 | −$60.1K | −4.1%62.8K after | |
| Apr 7, 2026 (view filing) | Apr 7 | Same day | Kihara JamesPRINCIPAL ACCOUNTING OFFICER | SSale | −1.03K | $22.20 | −$22.9K | −3.6%27.9K after | |
| Mar 26, 2026 (view filing) | Mar 25-26 | 1 day | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | SSale | −7.38K | $21.55 | −$159.1K | −10.9%60.3K after | 3 lots |
Top 10 13F holders, Q2 2026
See all 354 holdersThe largest institutional positions in Acadia Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 42,912,904 | $1.09B | 5.44% | +16,2140.0% | Added |
| BlackRock, Inc. | 22,515,173 | $569.6M | 0.01% | +964,252+4.5% | Added |
| State Street Corp | 9,076,212 | $229.6M | 0.01% | +743,441+8.9% | Added |
| Vanguard Portfolio Management LLC | 8,838,450 | $223.6M | 0.01% | +166,805+1.9% | Added |
| RTW Investments, LP | 7,144,524 | $180.8M | 1.54% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 5,763,750 | $145.8M | 0.00% | +102,350+1.8% | Added |
| Dimensional Fund Advisors LP | 3,694,988 | $93.5M | 0.02% | +539,828+17.1% | Added |
| Geode Capital Management, LLC | 3,358,129 | $85.0M | 0.00% | −106,560−3.1% | Reduced |
| Palo Alto Investors LP | 2,864,096 | $72.5M | 10.01% | −8,599−0.3% | Reduced |
| Goldman Sachs Group Inc | 2,580,115 | $65.3M | 0.01% | +1,022,311+65.6% | Added |
Holders of 5% or more of ACAD
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Acadia Pharmaceuticals Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 13D/A | 25.40%43.3M shares | – | Jan 17, 20233 filings | Feb 26, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 11.90%19.9M shares | – | Feb 7, 20251 filing | Feb 7, 2025 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.15%8.78M shares | New | Apr 28, 20261 filing | Apr 28, 2026 | SEC |
Politician trades
All politician trades in ACAD1 member of Congress reported 2 trades in Acadia Pharmaceuticals Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Jul 28, 2022 |  Chris Jacobs House · NY | Sell | $1K-$15K |
| Nov 6, 2020 | Chris Jacobs House · NY | Sell (partial) | $1K-$15K |
House · NY · Jul 28, 2022
Sell$1K-$15K
House · NY · Nov 6, 2020
Sell (partial)$1K-$15K